Higher-dose corticosteroids linked to increased risk of death in some hypoxic COVID-19 patients

A new study to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen April 15-18), and published in The Lancet, shows that compared with standard care that included low-dose corticosteroid use, treating hypoxic COVID-19 patients needing only oxygen therapy or no breathing support with higher-dose corticosteroids is associated with a 60% increased risk of death.